Those with an interest in optimising treatments for basel cell carcinoma (BCC) are encouraged to seize the opportunity to assess a newly available OCT scanner- VivoSight, which is over in Australia from London.
OCT scans provide high-resolution sub-surface images of BCC for treatment planning and monitoring. The company is prepared to lend it to a clinician/clinic on a first-come-first-serve basis for evaluation. Currently used at the Melanoma Institute of Australia by Pascale Guitera, as well as Robert Stephens at North West Sydney Dermatology and Laser. If you are interested, your first point of call is to email Lawrence at VivoSight.